204 related articles for article (PubMed ID: 21572547)
21. RNA biomarkers in colorectal cancer.
Bustin SA; Murphy J
Methods; 2013 Jan; 59(1):116-25. PubMed ID: 23079397
[TBL] [Abstract][Full Text] [Related]
22. Personalized Medicine-Current and Emerging Predictive and Prognostic Biomarkers in Colorectal Cancer.
Koulis C; Yap R; Engel R; Jardé T; Wilkins S; Solon G; Shapiro JD; Abud H; McMurrick P
Cancers (Basel); 2020 Mar; 12(4):. PubMed ID: 32231042
[TBL] [Abstract][Full Text] [Related]
23. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: beyond KRAS mutations.
Custodio A; Feliu J
Crit Rev Oncol Hematol; 2013 Jan; 85(1):45-81. PubMed ID: 22647972
[TBL] [Abstract][Full Text] [Related]
24. Molecular predictive and prognostic markers in colon cancer.
Winder T; Lenz HJ
Cancer Treat Rev; 2010 Nov; 36(7):550-6. PubMed ID: 20363564
[TBL] [Abstract][Full Text] [Related]
25. Gene expression profiling for guiding adjuvant chemotherapy decisions in women with early breast cancer: an evidence-based and economic analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(23):1-57. PubMed ID: 23074401
[TBL] [Abstract][Full Text] [Related]
26. Pharmacogenomic-Guided Therapy in Colorectal Cancer.
Diasio RB; Innocenti F; Offer SM
Clin Pharmacol Ther; 2021 Sep; 110(3):616-625. PubMed ID: 34114648
[TBL] [Abstract][Full Text] [Related]
27. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy.
Edler D; Glimelius B; Hallström M; Jakobsen A; Johnston PG; Magnusson I; Ragnhammar P; Blomgren H
J Clin Oncol; 2002 Apr; 20(7):1721-8. PubMed ID: 11919227
[TBL] [Abstract][Full Text] [Related]
28. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
29. Implementing prognostic and predictive biomarkers in CRC clinical trials.
Van Schaeybroeck S; Allen WL; Turkington RC; Johnston PG
Nat Rev Clin Oncol; 2011 Feb; 8(4):222-32. PubMed ID: 21321566
[TBL] [Abstract][Full Text] [Related]
30. Role of genomic markers in colorectal cancer treatment.
Allen WL; Johnston PG
J Clin Oncol; 2005 Jul; 23(20):4545-52. PubMed ID: 16002846
[TBL] [Abstract][Full Text] [Related]
31. Alternative spliced variants as biomarkers of colorectal cancer.
Yi Q; Tang L
Curr Drug Metab; 2011 Dec; 12(10):966-74. PubMed ID: 21787266
[TBL] [Abstract][Full Text] [Related]
32. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
33. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
[TBL] [Abstract][Full Text] [Related]
34. Molecular characterization of colorectal neoplasia in translational research.
Grizzle WE; Manne U; Jhala NC; Weiss HL
Arch Pathol Lab Med; 2001 Jan; 125(1):91-8. PubMed ID: 11151060
[TBL] [Abstract][Full Text] [Related]
35. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
[TBL] [Abstract][Full Text] [Related]
36. Precision medicine for adjuvant chemotherapy of resected colorectal cancer.
Miyamoto Y; Hiyoshi Y; Sawayama H; Tokunaga R; Baba H
Ann Gastroenterol Surg; 2020 Nov; 4(6):635-645. PubMed ID: 33319153
[TBL] [Abstract][Full Text] [Related]
37. Translating colorectal cancer genetics into clinically useful biomarkers.
Morley-Bunker A; Walker LC; Currie MJ; Pearson J; Eglinton T
Colorectal Dis; 2016 Aug; 18(8):749-62. PubMed ID: 26990814
[TBL] [Abstract][Full Text] [Related]
38. Molecular Testing for the Treatment of Advanced Colorectal Cancer: An Overview.
Lin PS; Semrad TJ
Methods Mol Biol; 2018; 1765():281-297. PubMed ID: 29589315
[TBL] [Abstract][Full Text] [Related]
39. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma.
Elsaleh H; Powell B; McCaul K; Grieu F; Grant R; Joseph D; Iacopetta B
Clin Cancer Res; 2001 May; 7(5):1343-9. PubMed ID: 11350904
[TBL] [Abstract][Full Text] [Related]
40. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
